<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995965</url>
  </required_header>
  <id_info>
    <org_study_id>8297</org_study_id>
    <nct_id>NCT04995965</nct_id>
  </id_info>
  <brief_title>Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg</brief_title>
  <acronym>CARBA</acronym>
  <official_title>Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg - Descriptive Epidemiology and Risk Factors for Infection in the Event of Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections with enterobacteria producing carbapenemases at the University Hospitals of&#xD;
      Strasbourg - descriptive epidemiology and risk factors for infection in the event of&#xD;
      colonization&#xD;
&#xD;
      There is a worrying situation of an increase in the number of patients colonized with&#xD;
      carbapenemase-producing Enterobacteriaceae (CPE) at HUS.&#xD;
&#xD;
      7 to 15% of patients colonized with EPC would develop an infection with EPC. The cohorts&#xD;
      published mainly concern patients hospitalized in intensive care. The associated mortality&#xD;
      reported in the literature is high (&gt; 25%) and greater than that associated with infection&#xD;
      with the same bacterium sensitive to carbapenems.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">January 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of Enterobacteriaceae infections producing carbapenemases</measure>
    <time_frame>Files analysed retrospectively from January 01, 2011 to July 31, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Nfections, Enterobacterial</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major subject with clinical sample or rectal screening smear finding an enterobacterium&#xD;
        producing a carbapenemase&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major subject (≥18 years old)&#xD;
&#xD;
          -  Subject hospitalized at HUS between 01/01/2011 and 07/31/2021&#xD;
&#xD;
          -  Clinical sample or rectal screening smear finding an enterobacterium producing a&#xD;
             carbapenemase (EPC)&#xD;
&#xD;
          -  Subject not having expressed their opposition to participating in the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  Subject under guardianship or guardianship&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yves HANSMANN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves HANSMANN, MD, PhD</last_name>
    <phone>33 3 69 55 09 78</phone>
    <email>yves.hansmann@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves HANSMANN, MD, PhD</last_name>
      <phone>33 3 69 55 09 78</phone>
      <email>yves.hansmann@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Yves HANSMANN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baptiste HOELLINGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucile HAUMESSER, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nfections, Enterobacterial</keyword>
  <keyword>carbapenemases</keyword>
  <keyword>producers of a carbapenemase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

